The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.

Journal article

Hepatitis C virus (HCV) readily sets up a persistent infection and is a major cause of liver disease worldwide. Interferon alfa and ribavirin therapy lead to sustained clearance of virus in 31% to 64% of patients with type 1 and non-type 1 genotypes, respectively. It is not clear to what extent these drugs act directly to reduce HCV replication, or indirectly via host immune responses, and what evoked immune responses are associated with clinical outcome. We have examined prospectively 15 pat...

Expand abstract

Authors: Barnes, E; Harcourt, G; Brown, D; Lucas, M; Phillips, R

• Publication status: Published
• Journal: Hepatology (Baltimore, Md.)
• Volume: 36
• Issue: 3
• Pages: 743-754
• Publication date: 2002-09-01
• DOI: 10.1053/jhep.2002.35344
• EISSN: 1527-3350
• ISSN: 0270-9139
• Language: English
• Keywords: Hepatitis C, Chronic; CD4-CD8 Ratio; Amino Acid Sequence; CD4-Positive T-Lymphocytes; Humans; Interferon-gamma; Molecular Sequence Data; Viral Core Proteins; Adult; Middle Aged; Female; Drug Therapy, Combination; Hepatitis C Antigens; CD8-Positive T-Lymphocytes; Cell Division; Biological Evolution; Prospective Studies; Cohort Studies; Mutation; Antiviral Agents; Male